Close Menu

NEW YORK — InBios International said on Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for its second SARS-CoV-2 antibody test.

The latest EUA is for the company's SCoV-2 Detect IgM ELISA kit, which is designed to qualitatively detect immunoglobulin M antibodies against SARS-CoV-2 in human serum. The kit includes all reagents and controls to run 90 test specimens with results available in about two hours. According to InBios, the test has demonstrated 92.5 percent sensitivity and 98.9 percent specificity in performance testing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.